Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Ibara will drive AI-powered clinical research innovation
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
Subscribe To Our Newsletter & Stay Updated
